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Abstract 
Neuroleptic malignant syndrome (NMS) is a
rare but potentially fatal disease characterized
by fever, muscle rigidity, delirium and autonom-
ic instability. Here we report a child, with NMS
due to the risperidone misdiagnosed as status
epilepticus. Nine year old boy, who had been
under  high  dose  risperidone  treatment  for  8
weeks,  admitted  to  the  emergency  room
because of the contractions (evaluated as status
epilepticus) persisting for 7 hours. Since there
was neuroleptic treatment in the past medical
history and, unconsciousness, muscular rigidi-
ty, diaphoresis, hypertermi and, hypotension in
physical examination, leucocytosis and elevated
creatininphosphokinase  levels  in  laboratory
tests, the patient was evaluated as NMS and dis-
charged without any complications. We reported
this case to point out that; NMS may be misdi-
agnosed as status epilepticus in children when
EEG monitoring is unavailable. When a child
admitted  to  the  emergency  room  because  of
suspicious  convulsion  neuroleptic  drug  use
must surely be asked. 
Introduction
Neuroleptic malignant syndrome (NMS) is a
rare but potentially fatal disease characterized
by fever, muscular rigidity, delirium and auto-
nomic instability.1 Yearly prevalence of the dis-
ease in patients under neuroleptic treatment
ranges between 0.02% and 2.4%. Mortality rate
of the patients without specific treatment is
approximately  21%.2,3 Mortality  rate  may  be
higher in patiens with misdiagnosis like our
patient. The classic presentation of this syn-
drome  has  been  most  commonly  associated
with  the  typical  neuroleptic  drugs  such  as
haloperidol.2
Risperidone  is  a  new  atypical  neuroleptic
agent.  5-HT2A  antagonism  partially  protects
against D2 antagonist-induced-neurologic side
effects and, may improve negative symptoms
and  cognitive  functioning  via  modulation  of
mesocortical DA activity. In addition, blockade
of  adrenoceptors  may  further  increase  pre-
frontal  cortical  activity  and  could  enhance
antipsychotic  efficacy  by  modulations  of
mesolimbic DA activity. Unlike other atypical
agents, risperidone does not differ from con-
ventional agents in its dissociation contrast for
D2 receptor; this feature perhaps accounts for
the risk of EPS (extrapyramidal side effects) at
high  doses.4 However  in  large  multicentre
studies it was shown that risperidone had sim-
ilar side effects like other typical neuroleptic
agents.5As far as we know the number of cases
due to risperidone treatment in the literature
is limited and most of the reported cases are
adults.  In  most  of  these  cases  risperidone
induces NMS after two weeks of treatment.6
Here  we  report  a  child  with  NMS  due  to
risperidone treatment who was misdiagnosed
as  status  epilepticus.  The  patient  reported
here met DSM-IV criteria for NMS.1
Case Report
Nine  years  old  boy  was  admitted  to  the
emergency department because of the convul-
sions persisting for seven hours. He had atten-
tion deficit hyperactivity disorder and he had
been  under  risperidone  (2¥2  mg/day)  treat-
ment orally for 8 weeks because of moderate
mental retardation and psychological disorder.
Risperidone dose was four times more than
usually  recommended  pediatric  dosage.
Additionally  the  patient  had  been  suffering
vomiting, tremor and fever for two weeks. 
Physical  examination  in  the  emergency
room revealed a body temperature of 39°C, a
respiratory rate of 10 breaths/min, and, a pulse
rate of 158 beats/min. Blood pressure was too
low that it couldn’t be measured initially. The
patient’s  general  appearance  was  lethargic.
There  was  muscular  rigidity,  tremor  and,
diaphoresis. He was dehydrated. Heart sounds
were rhythmic and tachycardic. His respiration
was weak and respiratory sounds were normal.
Bilateral  pupil  reflexes  were  positive.  Deep
tendon  reflexes  were  brisk  and  bilateral
Babinski reflexes were positive. There were no
meningeal irritation signs.
Initial laboratory analysis revealed a white
blood cell count of 21580 cells/mm3, with 2%
band neutrophils, 62% neutrophils, 30% lym-
phocytes,  6%  monocytes.  Serum  electrolytes
were in normal ranges included a sodium level
of 136 mEq/L; potassium, 5.4 mEq/L; chloride
105 mEq/L and, calcium 8.2 mEq/L. The blood
glucose  was  316  mg/dl.  Initial  venous  blood
gases showed a pH of 7.04; carbon dioxide ten-
sion 95 mmHg; bicarbonate 26 mEq/L and, base
excess,  -5.8  mmol/L.  The  serum  creatinine
phosphokinase  (CPK)  level  was  1658  U/L.
Blood, urine and stool cultures were negative.
Urinalysis, chest radiograph, cranial CT and
EEG were unremarkable.
Although the tremors accompany muscular
rigidity were mimicking convulsions and the
patient  was  admitted  with  staus  epilepticus
diagnosis, the patient was not diagnosed as
status  epilepticus  because  there  were  neu-
roleptic treatment in his medical history, mus-
cular  rigidity,  diaphoresis,  hypertermi  and
hypotension in physical examination, leucocy-
tosis  and  elevated  CPK  levels  in  laboratory
tests.  By the help of the sign and symptoms
above, the patient was diagnosed as NMS by
pediatric  critical  care  intensivist,  pediatric
neurologist  and  pediatric  psychiatrist.  NMS
diagnosis was confirmed with EEG and risperi-
done treatment was ceased.
In  the  emergency  department  the  patient
was entubated because of respiratory failure.
Then he was admitted to the pediatric inten-
sive  care  unit  and  mechanically  ventilated.
Intravenous  diazepam  infusion  (0.3  mg/kg
hour) and carbidopa/levodopa were given for
NMS treatment. In the first day of the admis-
sion to the intensive care unit the patient had
hyperthermia resistant to the antipyretic treat-
ment  and  his  blood  pressure  was  unstable.
Central venous catheter was placed and hemo-
dynamic parameters of the patient were regu-
lated in normal ranges. In the second day of
the admission to the intensive care unit the
patient was extubated. All the clinical and lab-
oratory  signs  and  symptoms  of  the  patient
improved except elevated creatinin phosphoki-
nase levels which turned back to normal values
on the fifth day of the admission. Then he was
discharged from the hospital without compli-
cations.
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Discussion
Here we report a patient with NMS who was
misdiagnosed  as  status  epilepticus  before
admission  to  our  hospital.  Our  patient  was
diagnosed as NMS due to presence of men-
tioned criteria of NMS.1 Mortality rate of NMS
in the patients without specific treatment is
approximately  21%.2,3 Mortality  rate  may  be
higher  in  patiens  with  misdiagnosis.    NMS
signs and symptoms may be difficult to differ-
entiate  from  status  epilepticus  by  inexperi-
enced  physicians  when  EEG  monitoring  is
unavailable. As mentioned before, our patient
was diagnosed as status epilepticus before he
was admitted to our hospital and he had been
tried to be treated as status epilepticus at the
beginning. 
The  clinical  signs  and  symptoms  of  our
patient  emerged  in  the  second  week  of  the
risperidone treatment. As it was pointed out
before NMS may occur in anytime during neu-
roleptic treatment.6
First step of the NMS treatment is to cease
antipsychotic drugs. After we diagnosed NMS
we  discontinued  the  risperidone  treatment.
Cooler blankets and antipyretics for hyperther-
mia and supportive treatment including fluid
electrolyte therapy must be supplied. In med-
ical  treatment  in  order  to  reduce  muscular
rigidity dopamine agonists are used. Similarly
we  used  dopamine  agonists  for  our  patient.
Additionally dantrolene may be used alone or
with dopamine.
Previously it was thought that NMS was only
associated with the use of classical neurolep-
tics. However there are some NMS cases due
to atypical neuroleptics in the literature.7 As
far as we know in the literature only two NMS
cases  due  to  risperidone  treatment  were
reported in children.8,9 We think that atypical
neuroleptics will be extensively used in chil-
dren in the future and the clinicians especial-
ly the pediatricians must be familiar to NMS
and its differential diagnosis.
We report this case in order to underline
that neuroleptic malignant syndrome may be
misdiagnosed as status epilepticus in children
when EEG monitoring is unavailable. When a
child is admitted to the emergency department
because of unconsciouesness muscular rigidi-
ty,  diaphoresis,  hypertermi  and  hypotension;
neuroleptic  drug  use  must  surely  be  asked.
Furthermore  this  is  the  third  neuroleptic
malignant syndrome case due to risperidone
treatment  in  children.  Early  diagnosis  and
proper  treatment  of  NMS  may  decrease  the
mortality rates significantly. 
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